Seres Therapeutics, Inc.
MCRBNasdaq
$5.33
↑ +2.9%Jul 17 close · end-of-day
Price
1Y↓ -61.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$51.1M
Enterprise Value
$21.2M
P/E
—
P/S
—
P/B
1.9
EV/EBITDA
—
PEG
—
FCF Yield
-83.0%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$46.9M
Free Cash Flow (TTM)
-$42.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-177.0%
ROIC
—
Debt / Equity
—
Net Cash
$29.8M
Return 1Y
-62.1%
Company profile
Seres Therapeutics, Inc. engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection. SER-155, a cultivated bacteria microbiome drug, is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases.
- CEO
- Eric D. Shaff
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 330
- Headquarters
- Massachusetts
- Website
- serestherapeutics.com
Management & directors
- Brady KellySee Remarks
- Desrosier ThomasSee Remarks
- Henn Matthew R.See Remarks
- Young Teresa L.See Remarks
Roles derived from SEC Form 4 filings.
Earnings
MCRB Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$358,000.00—
Diluted EPS-$2.08↓ -155.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $33.2M | $144.9M | $7.1M | $0.00 | $0.00 | $789,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$88.1M | -$64.5M | -$179.9M | -$195.1M | -$121.3M | -$94.0M |
| Net income | -$89.1M | -$65.6M | -$250.2M | -$113.7M | $136,000.00 | $5.7M |
| Diluted EPS | -$1.12 | -$0.72 | -$2.31 | -$17.77 | $0.00 | $0.64 |
| Operating cash flow | -$93.6M | $6.7M | -$228.8M | -$117.4M | -$148.6M | $1.1M |
| Free cash flow | -$94.2M | -$2.9M | -$238.6M | -$125.3M | -$149.0M | $865,000.00 |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -265.3% | -44.5% | -2524.0% | — | — | -11910.1% |
| Net margin | -268.3% | -45.2% | -3509.5% | — | — | 721.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | $351,000.00 | — | $358,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$28.9M | -$29.2M | -$28.8M | -$27.2M | -$24.9M | -$22.5M | -$19.4M | -$20.9M |
| Net income | -$32.9M | $88.8M | -$15.6M | $32.7M | -$19.9M | $8.2M | -$15.3M | -$19.9M |
| Diluted EPS | -$4.34 | $11.63 | -$1.80 | $3.75 | -$2.27 | $0.94 | -$1.78 | -$2.08 |
| Operating cash flow | -$39.8M | -$34.7M | -$38.9M | $26.9M | -$13.3M | $2.2M | -$14.7M | -$16.4M |
| Free cash flow | -$39.9M | -$34.8M | -$39.0M | $26.9M | -$13.5M | $2.2M | -$14.7M | -$16.4M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -6403.7% | — | -5839.9% |
| Net margin | — | — | — | — | — | 2337.3% | — | -5562.3% |
Company news
Jun 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-18 | Shaff Eric D. | Sale | 259 | $7.53 | $1,950.27 | filing |
| 2026-05-18 | DesRosier Thomas· See Remarks | Sale | 79 | $7.53 | $594.87 | filing |
| 2026-05-18 | Henn Matthew R.· See Remarks | Sale | 77 | $7.53 | $579.81 | filing |
| 2026-05-18 | Brady Kelly· See Remarks | Sale | 59 | $7.53 | $444.27 | filing |
| 2026-05-15 | DesRosier Thomas· See Remarks | Option exercise | 244 | — | — | filing |
| 2026-05-15 | Shaff Eric D. | Option exercise | 722 | — | — | filing |
| 2026-05-15 | Henn Matthew R.· See Remarks | Option exercise | 238 | — | — | filing |
| 2026-05-15 | Brady Kelly· See Remarks | Option exercise | 180 | — | — | filing |
| 2026-02-15 | Shaff Eric D. | Sale | 259 | $8.47 | $2,193.73 | filing |
| 2026-02-15 | Henn Matthew R.· See Remarks | Sale | 89 | $8.47 | $753.83 | filing |
| 2026-02-15 | DesRosier Thomas· See Remarks | Sale | 78 | $8.47 | $660.66 | filing |
| 2026-02-15 | Young Teresa L.· See Remarks | Sale | 75 | $8.47 | $635.25 | filing |
| 2026-02-15 | Young Teresa L.· See Remarks | Option exercise | 231 | — | — | filing |
| 2026-02-15 | DesRosier Thomas· See Remarks | Option exercise | 244 | — | — | filing |
| 2026-02-15 | Henn Matthew R.· See Remarks | Option exercise | 239 | — | — | filing |
| 2026-02-15 | Shaff Eric D. | Option exercise | 723 | — | — | filing |
| 2025-11-15 | Henn Matthew R.· See Remarks | Sale | 1,257 | $17.30 | $21,746.10 | filing |
| 2025-11-15 | Young Teresa L.· See Remarks | Sale | 1,042 | $17.30 | $18,026.60 | filing |
| 2025-11-15 | Shaff Eric D. | Sale | 217 | $17.30 | $3,754.10 | filing |
| 2025-11-15 | DesRosier Thomas· See Remarks | Sale | 76 | $17.30 | $1,314.80 | filing |
| 2025-11-15 | Shaff Eric D. | Option exercise | 331 | — | — | filing |
| 2025-11-15 | DesRosier Thomas· See Remarks | Option exercise | 132 | — | — | filing |
| 2025-11-15 | DesRosier Thomas· See Remarks | Option exercise | 112 | — | — | filing |
| 2025-11-15 | Henn Matthew R.· See Remarks | Option exercise | 3,998 | — | — | filing |
| 2025-11-15 | Henn Matthew R.· See Remarks | Option exercise | 140 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.